EP1383543A4 - USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS - Google Patents

USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS

Info

Publication number
EP1383543A4
EP1383543A4 EP02726668A EP02726668A EP1383543A4 EP 1383543 A4 EP1383543 A4 EP 1383543A4 EP 02726668 A EP02726668 A EP 02726668A EP 02726668 A EP02726668 A EP 02726668A EP 1383543 A4 EP1383543 A4 EP 1383543A4
Authority
EP
European Patent Office
Prior art keywords
visualization
treatment
brain tumors
biomolecular targets
biomolecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02726668A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1383543A1 (en
Inventor
Sabine Mueller
Thorsten Melcher
Daniel J Chin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGY Therapeutics Inc
Original Assignee
AGY Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/816,703 external-priority patent/US6455026B1/en
Priority claimed from US09/983,000 external-priority patent/US20030118585A1/en
Application filed by AGY Therapeutics Inc filed Critical AGY Therapeutics Inc
Publication of EP1383543A1 publication Critical patent/EP1383543A1/en
Publication of EP1383543A4 publication Critical patent/EP1383543A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP02726668A 2001-03-23 2002-03-22 USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS Withdrawn EP1383543A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US983000 1992-11-30
US816703 2001-03-23
US09/816,703 US6455026B1 (en) 2001-03-23 2001-03-23 Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
US09/983,000 US20030118585A1 (en) 2001-10-17 2001-10-17 Use of protein biomolecular targets in the treatment and visualization of brain tumors
PCT/US2002/008992 WO2002076510A1 (en) 2001-03-23 2002-03-22 Use of biomolecular targets in the treatment and visualization of brain tumors

Publications (2)

Publication Number Publication Date
EP1383543A1 EP1383543A1 (en) 2004-01-28
EP1383543A4 true EP1383543A4 (en) 2006-06-21

Family

ID=27124105

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02726668A Withdrawn EP1383543A4 (en) 2001-03-23 2002-03-22 USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS

Country Status (4)

Country Link
EP (1) EP1383543A4 (cg-RX-API-DMAC10.html)
JP (1) JP2004537282A (cg-RX-API-DMAC10.html)
CA (1) CA2439630A1 (cg-RX-API-DMAC10.html)
WO (1) WO2002076510A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US7678769B2 (en) * 2001-09-14 2010-03-16 Compugen, Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
WO2007036945A2 (en) 2005-09-30 2007-04-05 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
WO2005014022A1 (en) 2003-07-16 2005-02-17 Develogen Aktiengesellschaft Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2006029462A1 (en) * 2004-09-14 2006-03-23 Autogen Research Pty Ltd A nucleic acid molecule differentially expressed in a mouse behavioural model system and uses thereof
ES2828739T3 (es) * 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
WO2009007934A2 (en) 2007-07-10 2009-01-15 Neurim Pharmaceuticals (1991) Ltd. Cd44 splice variants in neurodegenerative diseases
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN121249676B (zh) * 2025-12-05 2026-03-24 重庆医科大学附属第一医院 一种met二聚体靶向的放射性核素探针及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323884D0 (en) * 1993-11-19 1994-01-05 Eisai London Res Lab Ltd Physiological modulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER LETTERS, vol. 156, no. 2, 11 August 2000 (2000-08-11), pages 191 - 198, ISSN: 0304-3835 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 11 August 2000 (2000-08-11), KROES ROGER A ET AL: "The identification of novel therapeutic targets for the treatment of malignant brain tumors", XP002379786, Database accession no. PREV200000425434 *
See also references of WO02076510A1 *

Also Published As

Publication number Publication date
CA2439630A1 (en) 2002-10-03
JP2004537282A (ja) 2004-12-16
WO2002076510A1 (en) 2002-10-03
EP1383543A1 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
IL158273A0 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU2002243495A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EP1641378A4 (en) METHOD AND DEVICES FOR TREATING SKIN Lions
EP1392818A4 (en) FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR
AU2003291609A1 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
SI1575597T1 (sl) Uporaba rimeksolona pri zdravljenju suhega očesa
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
HUP0500424A2 (en) Combination therapy for the treatment of cancer
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
AU2003212634A8 (en) Compounds useful in the treatment of cancer
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
GB0108671D0 (en) Skin treatment
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2002340251A8 (en) Use of mx gtpases in the prognosis and treatment of cancer
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
EP1328264A4 (en) USE OF ESTRAMUSTINE PHOSPHATE IN THE TREATMENT OF BONE METASTASE
AU2002328383A1 (en) Equipment for treating painful points in the organism
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060524

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060831